Episode notes
CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.
In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.
Launch/Release Date: December 17, 2025
Activity Expiration Date: November 30, 2026
FACULTY
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
Professor, Clinical Genomics and Therapeutics
Translational Genomics R ...